RARA CRAFT DATABASE for FDA Medical Devices
510(k)K230875

FDA DEVICE FACTS

Blue Non Sterile Powder Free Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs, with Gastric Acid and Fentanyl Permeation Resistance Claims

Central Medicare Sdn Bhd

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJuly 20, 2023PRODUCT CODELZA

Indications for use

Blue Non Sterile Powder Free Nitrile Examination Gloves, Tested for Use with Chemotherapy Drugs, with Gastric Acid and Fentanyl Permeation Resistance Claims is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs, with gastric acid and fentanyl citrate in accordance with ASTM D6978-05. Tested for Use with Chemotherapy Drugs - Gloves have been tested for use with chemotherapy drugs using ASTM D6978-05 and will be labeled with a statement of compliance and a summary of the testing results. Tested chemotherapy drugs and average breakthrough detection time (minutes) are as follows: Chemotherapy Drug Arsenic Trioxide Azacitidine (Vidaza) Bendamustine HCl Bleomycin Sulfate Busulfan Carboplatin Carmustine (BCNU) Carfilzomib Cisplatin Cladribine Cyclophosphamide (Cytoxan) Cytarabine Dacarbazine Daunorubicin Decitibine Docetaxel Doxorubicin Hydrochloride Epirubicin (Ellence) Etoposide (Toposar) Fludarabine Fluorouracil Gemcitabine (Gemzar) Idarubicin Ifosfamide Irinotecan Mechlorethamine HCI Melphalan Mesna Methotrexate Mitomycin C Mitoxantrone Oxaliplatin Paclitaxel Breakthrough Detection Time in Minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes 77.6 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes Concentration 1.0 mg/ml 25.0 mg/ml 5.0 mg/ml 15.0 mg/ml 6.0 mg/ml 10.0 mg/ml 3.3 mg/ml 2.0 mg/ml 1.0 mg/ml 1.0 mg/ml 20.0 mg/ml 100.0 mg/ml 10.0 mg/ml 5.0 mg/ml 5.0 mg/ml 10.0 mg/ml 2.0 mg/ml 2.0 mg/ml 20.0 mg/ml 25.0 mg/ml 50.0 mg/ml 38.0 mg/ml 1.0 mg/ml 50.0 mg/ml 20.0 mg/ml 1.0 mg/ml 5.0 mg/ml 50.0 mg/ml 25.0 mg/ml 0.5 mg/ml 2.0 mg/ml 2.0 mg/ml 6.0 mg/ml Paraplatin Pemetrexed Pertuzumab Raltitrexed Retrovir Temsirolimus Thiotepa Topotecan HCI Trisenox (Arsenic Trioxide) Velcade (Bortezomib) Vinblastine Vincristine Sulfate Vinorelbine 10.0 mg/ml 25.0 mg/ml 30.0 mg/ml 0.5 mg/ml 10.0 mg/ml 25.0 mg/ml 10.0 mg/ml 1.0 mg/ml 1.0 mg/ml 1.0 mg/ml 1.0 mg/ml 1.0 mg/ml 10.0 mg/ml > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes Tested non-chemotherapy drugs and average breakthrough detection time (minutes) are as follows: Non-Chemotherapy Drug Cetuximab Chloroquine Cyclosporin A Cytovene (Ganciclovir) Fulvestrant Propofol Rituximab Trastuzumab Triclosan Zoledronic Acid Breakthrough Detection Time in Minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes > 240 minutes Concentration 2.0 mg/ml 50.0 mg/ml 100.0 mg/ml 10.0 mg/ml 50.0 mg/ml 10.0 mg/ml 10.0 mg/ml 21.0 mg/ml 2.0 mg/ml 0.8 mg/ml Fentanyl Permeation Resistance Claims - Under the testing conditions of ASTM D6978-05, Fentanyl Citrate Injection (100mcg/2mL) was found to have no breakthrough detected up to 240 minutes. Gastric Acid Permeation Resistance Claims - Under the testing conditions of ASTM D6978-05, was found to have no breakthrough detected up to 240 minutes. CAUTION: Testing showed an average breakthrough time of 77.6 minutes with Carmustine. WARNING: Do not use with Carmustine.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 18, 2026